PTGX compared with RDNT: revenue, margins and what each company keeps, and the suppliers and customers both name

PTGXProtagonist Therapeutics, Inc

Mkt capRevenueRevenue

RDNTRadNet, Inc.

Mkt capRevenueRevenue

Compare

PTGXProtagonist Therapeutics, Inc

RDNTRadNet, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PTGX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Nov 6 '26thin chain±8.1%▼−2.38%×0.30

Aug 6 '26±11.8%▲+6.45%×0.55

May 6 '26±5.3%▲+4.80%×0.91

Feb 26 '26±9.0%▲+1.48%×0.17

RDNT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Aug 10 '26±10.8%▲+6.76%×0.63

May 11 '26±9.0%▼−3.94%×0.43

= impliedPTGX realized, solidRDNT realized, hatchedOne scale, both sides: full bar = 13%× = |realized| ÷ impliedSource: market data

Mar 2 '26

±11.6%

▲+7.75%

×0.67

Nov 10 '25±12.3%▲+3.24%×0.26

PTGXProtagonist Therapeutics, Inc

132.31▼−2.18%· post 132.31

Mkt cap$8.6BRevenue$274MQ3 FY26Revenue$46MFY25

RDNTRadNet, Inc.

75.83▼−2.79%· post 75.83

ClosedNov 6 '26

Mkt cap$6.0BRevenue$623MQ2 FY26Revenue$2.0BFY25

Compare

ClosedNov 6 '26

PTGXProtagonist Therapeutics, Inc

RDNTRadNet, Inc.

132.31▼−2.18%post 132.31

Price

75.83▼−2.79%post 75.83

$8.6B

Mkt cap

$6.0B

Q3 FY26$274M

Revenue

$623MQ2 FY26

FY25$46M

Revenue

$2.0BFY25

PTGX132.31▼−2.18%vsRDNT75.83▼−2.79%ClosedNov 6 '26